Impact of Probiotics in Modulation of Intestinal Microbiota

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-07-31

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators would study about impact of the administration of probiotics in the intestinal mucosa of patients undergoing resection colic, by evaluating cytokine profile by quantitative real time PCR. The investigators believe that patients who use probiotic preoperative would provide cytokine profile less inflammatory than those of the control group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Colonoscopic Probiotics Infusion for Functional Gastrointestinal Disease

NCT05366335

Functional Constipation Irritable Bowel Syndrome Probiotics +1 more

UNKNOWN PHASE4

Efficacy of a Probiotic Blend to Reduce Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome

NCT05819281

Irritable Bowel Syndrome

UNKNOWN PHASE2

Effect of a Probiotic Formula on Reducing SIBO in IBS Patients

NCT04316806

Irritable Bowel Syndrome Small Intestinal Bacterial Overgrowth

TERMINATED NA

Efficacy of Probiotics in Patients With IBD

NCT05652621

Ulcerative Colitis Irritable Bowel Syndrome

RECRUITING NA

To Study the Effect of Short-chain Fructooligosaccharides in Women With Irritable Bowel Syndrome

NCT05941650

Irritable Bowel Syndrome Diarrhea- Irritable Bowel Syndrome Constipation-predominant Irritable Bowel Syndrome

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Samples of colorectal cancer-free mucosa derived from patients who underwent surgical resection were investigated. Quantitative real-time polymerase chain reaction (RT-qPCR) was used to determine expression levels of the following genes: IL10, IL1B, IL23A, TNF, IL12B, INFG, IL17A.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Conventional treatment with no probiotic supplementation

Group Type NO_INTERVENTION

No interventions assigned to this group

Probiotic group

The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.

Group Type EXPERIMENTAL

Saccharomyces boulardii

Intervention Type DIETARY_SUPPLEMENT

The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Saccharomyces boulardii

The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* if he or she were older than 18 years
* intended to undergo elective CRC resection at UFMG Hospital

Exclusion Criteria

* Patients were excluded if they were not able to receive the probiotics seven days before the operation
* if colon resection was not performed due to changes in operation strategy, or if they discontinued probiotic use on their own or
* if they removed their consent.

Eligible Sex

ALL

Accepts Healthy Volunteers

No